Liquid-liquid phase separation (LLPS) has emerged as a fundamental mechanism in neurodegenerative disease pathogenesis. The formation of biomolecular condensates—membrane-less organelles formed through LLPS—plays critical roles in both normal cellular function and pathological protein aggregation. Therapeutic modulation of LLPS represents a novel approach to target the earliest stages of protein aggregation across multiple neurodegenerative diseases[@banani2023][@liu2025].
This page covers therapeutic strategies targeting:
- Direct modulation of phase separation dynamics
- Condensate-dispersing compounds
- Nucleocytoplasmic transport restoration
- Stress granule normalization
LLPS represents an upstream intervention point in the neurodegeneration cascade:
- Early Intervention: Phase separation precedes solid aggregate formation
- Disease-Specific: Pathological condensates have distinct properties from physiological ones
- Multiple Disease Relevance: One mechanism spans AD, PD, ALS, HD, CBS, PSP, FTD
- Druggable: Protein-protein interactions driving LLPS are accessible to small molecules
- Aβ peptides undergo LLPS to form oligomeric assemblies before fibril formation
- Tau phase separation drives neurofibrillary tangle assembly
- Stress granule formation sequesters translation machinery
- α-synuclein phase separation is promoted by mutations (A53T, E46K)
- Progression from liquid droplets to solid Lewy bodies
- Stress granule abnormalities contribute to pathogenesis
- FUS mutations alter phase behavior, leading to gelation
- TDP-43 condensates lose nuclear import and form cytoplasmic aggregates
- Stress granule dysfunction sequesters essential nuclear factors
- Polyglutamine expansions drive pathological phase separation
- Mutant huntingtin forms condensates that sequester cellular components
- 4R tau variants undergo phase separation
- Stress granule dysfunction in 4R tauopathies
¶ 1,6-Hexanediol and Analogs
Mechanism: 1,6-hexanediol disrupts aromatic interactions that stabilize condensates. It specifically targets FUS and TAF15 phase separation by interfering with π-π interactions in low-complexity domains.
Target Proteins: FUS, TAF15
Development Stage: Preclinical
Evidence: In vitro studies show disruption of FUS liquid droplets; vivo studies in ALS models demonstrate reduced stress granule formation
Mechanism: Covalent modifier of G3BP1 that inhibits stress granule formation
Target: G3BP1 (stress granule scaffold protein)
Development Stage: Discovery phase
Evidence: Cell-based screens identify it as a stress granule inhibitor
Mechanism: Synthetic polymers that alter condensate material properties
Target: General LLPS modulation
Development Stage: Discovery phase
Evidence: Modulates phase behavior in cell models[@liu2025]
Mechanism: Restore nuclear import disrupted by pathological condensates
Target: Karyopherin-mediated transport
Development Stage: Discovery phase
Evidence: ALS models show that restoring import reduces FUS cytoplasmic aggregation
Mechanism: Modulate nucleocytoplasmic shuttling to reduce cytoplasmic condensate accumulation
Target: XPO1/CRM1
Development Stage: Preclinical
Evidence: Leptomycin B analog shows promise in ALS models
Mechanism: Prevent stress granule nucleation by inhibiting G3BP1
Target: G3BP1
Development Stage: Discovery phase
Mechanism: Alter stress granule dynamics to promote disassembly
Target: TIA1
Development Stage: Discovery phase
Drugs: Rapamycin, everolimus
Mechanism: Activate autophagy to clear pathological condensates
Clinical Trials: NCT03311187 (rapamycin in AD)
Status: Phase II
Mechanism: Enhance lysosomal biogenesis to clear condensates
Target: TFEB transcription factor
Development Stage: Preclinical
Rationale: CDK5 phosphorylation alters tau phase separation
Target: CDK5
Development Stage: Discovery phase
Rationale: GSK-3β phosphorylates tau and affects its phase behavior
Target: GSK-3β
Development Stage: Clinical trials in AD
¶ Drug Candidates Summary
| Compound |
Target |
Mechanism |
Disease |
Stage |
| 1,6-Hexanediol |
FUS/TAF15 |
Disrupt LLPS |
ALS/FTD |
Preclinical |
| 5-Octylitaconate |
G3BP1 |
Inhibit stress granules |
ALS |
Discovery |
| Rapamycin |
mTOR |
Autophagy enhancement |
AD |
Phase II |
| Nilotinib |
c-Abl |
Autophagy enhancement |
PD |
Phase II |
| Radotinib |
c-Abl |
Modulate α-syn LLPS |
PD |
Phase II |
| Importin modulators |
Importins |
Restore nuclear transport |
ALS |
Discovery |
| Amphiphilic polymers |
General LLPS |
Alter phase behavior |
Multiple |
Discovery |
¶ Clinical Trial Landscape
| Trial |
Drug |
Target |
Phase |
Disease |
| NCT02947822 |
Nilotinib |
c-Abl |
Phase II |
PD |
| NCT03311187 |
Rapamycin |
mTOR/autophagy |
Phase II |
AD |
| NCT03126603 |
Masitinib |
Tyrosine kinases |
Phase III |
ALS |
| Trial |
Drug |
Target |
Phase |
Disease |
Result |
| NCT01758930 |
Lithium |
GSK-3β |
Phase II |
ALS |
Completed |
| NCT02622555 |
Nilotinib |
c-Abl |
Phase I |
PD |
Completed |
flowchart TD
A["Pathological Condensate<br/>(FUS/TDP-43/α-syn)"] --> B["Small Molecule Entry"]
B --> C{"Mechanism Type"}
C --> D["Aromatic Interaction Block<br/>(1,6-hexanediol)"]
C --> E["Scaffold Protein Inhibition<br/>(G3BP1 inhibitors)"]
C --> F["Charge Modification<br/(Amphiphilic polymers)"]
D --> G["Condensate Disassembly"]
E --> G
F --> G
G --> H["Restore Cellular Homeostasis"]
style A fill:#ffcdd2,stroke:#333
style G fill:#c8e6c9,stroke:#333
style H fill:#c8e6c9,stroke:#333
Pathological condensates disrupt nuclear pore complex function, trapping proteins in the cytoplasm. Restoring transport:
- Importin modulation: Enhance nuclear import of proteins like TDP-43
- Exportin inhibition: Reduce aberrant cytoplasmic export
- Nuclear pore repair: Target proteins that restore NPC function
Stress granules become pathological in neurodegeneration:
- Persistent formation (failure to dissolve after stress)
- Sequestration of essential nuclear factors
- Transition from liquid to gel/solid states
Therapeutic approaches:
- Promote stress granule disassembly after stress resolution
- Prevent aberrant protein sequestration
- Block transition to pathological solid states
-
FRAP (Fluorescence Recovery After Photobleaching)
- Measures condensate dynamics
- Screens for compounds that restore流动性
-
DLS (Dynamic Light Scattering)
- Characterizes condensate size
- Identifies dispersal agents
-
Droplet assays
- In vitro phase separation reconstitution
- High-throughput compound screening
-
Stress granule induction assays
- Sodium arsenite treatment
- Compound screening for granule modulation
-
Disease mutant expression
- FUS, TDP-43, α-syn mutants
- Assess compound effects on aggregation
-
iPSC-derived neurons
- Patient-derived cells with disease mutations
- Physiologically relevant screening
- C. elegans - Transparent, rapid screening
- Drosophila - Genetic disease models
- Mouse models - Transgenic disease models
¶ Challenges and Considerations
- Physiological LLPS: Essential for normal cellular function
- On-target toxicity: Must avoid disrupting normal condensates
- Cell-type specificity: Different neurons vs. glia have different vulnerabilities
- Blood-brain barrier: Most small molecules don't penetrate
- Sustained exposure: Condensate clearance requires prolonged treatment
- Distribution: Must reach affected brain regions
- Causality: Is LLPS disruption sufficient for therapeutic benefit?
- Biomarkers: Need to measure target engagement
- Clinical endpoints: How to measure success?
- Heterotypic condensates: Mixed protein-RNA condensates
- Mitochondrial condensates: Novel organelle-specific targets
- Nucleolar stress: AD-specific LLPS involvement
- LLPS modulators + autophagy enhancers: Clear dispersed condensates
- LLPS modulators + kinase inhibitors: Target upstream and downstream
- Gene therapy + small molecules: Long-term expression with pharmacological support
- CSF condensate markers: FUS, TDP-43 in extracellular vesicles
- PET ligands: Imaging stress granules in vivo
- Blood-based assays: Circulating condensate components
- Banani et al., Biomolecular Condensates as Drug Targets (2023)
- Liu et al., Targeting Phase Separation in Neurodegenerative Disease (2025)
- Molliex et al., Phase Separation and Disease (2023)
- Wegmann et al., Tau Liquid Phase Separation (2024)
- Ferreira et al., α-Synuclein Phase Transitions (2025)
- Ambrose et al., ALS/FTD FUS Mutations Drive Aberrant Phase Separation (2024)
- Rao et al., Small Molecule Modulators of Phase Separation (2025)